News

The global pharmaceutical landscape is witnessing a significant surge in peptide research, manufacturing, and market reach, driven by strategic acquisitions and technological advancements. Major players are expanding their capacities to meet the growing demand for peptide-based therapeutics across various medical fields, from oncology to metabolic disorders.

Key Takeaways

• CordenPharma's acquisition of AmbioPharm significantly expands its global peptide API manufacturing capacity and technological expertise.
• The Peptide Drug Conjugates (PDC) market is projected for substantial growth, driven by oncology pipelines and expanding therapeutic applications.
• Innovations in collagen peptides are offering non-pharmaceutical solutions for health management, such as blood sugar regulation.

Strategic Expansion in Peptide Manufacturing

CordenPharma, a prominent global contract development and manufacturing organisation (CDMO), has announced the acquisition of AmbioPharm, a US-based peptide API CDMO. This strategic move enhances CordenPharma's existing global facility network, adding AmbioPharm's two sites in South Carolina and Shanghai. The integration aims to bolster capabilities in complex peptide programmes, offering customers greater geographic flexibility and scaled manufacturing options. This acquisition follows CordenPharma's continued expansion since being acquired by Astorg in 2022, underscoring a commitment to long-term growth in the peptide sector.

Peptide Drug Conjugates Market Growth

The global Peptide Drug Conjugates (PDC) market is on a trajectory for significant expansion, with projections indicating a compound annual growth rate of 12.8% through 2035. This growth is primarily fuelled by a robust pipeline of PDC candidates in clinical trials, particularly within oncology, and an increasing diversification of therapeutic applications beyond cancer to include inflammatory, metabolic, and infectious diseases. Key drivers include advancements in novel peptide scaffolds, expanded payload diversity, and strategic collaborations between biopharmaceutical companies and specialised CDMOs. However, the market faces constraints such as stringent regulatory scrutiny on conjugate heterogeneity and limited GMP manufacturing capacity for complex conjugation processes.

Innovations in Collagen Peptides

Beyond therapeutic applications, the field of peptides is also seeing innovation in nutritional supplements. Rousselot, a brand of Darling Ingredients, has secured a US patent for its collagen peptide ingredient, Nextida GC. This ingredient is designed to support healthy blood sugar levels post-meal through a non-pharmaceutical approach. The patent protects its use as a dietary supplement and its production process, highlighting the growing demand for science-backed nutritional solutions that offer natural alternatives for health management.

Sources

• Switzerland: CordenPharma expands global peptides platform in US and China, Investors in Healthcare.
• CordenPharma Acquires AmbioPharm To Expand Global Peptide API Capacity, Pulse 2.0.
• Peptide Drug Conjugates Market Growth Outlook to 2035: Demand Accelerates on Novel Payload Diversity - News
  and Statistics, IndexBox.
• Rousselot gains US patent for Nextida GC collagen peptide ingredient, Nutrition Insight.